Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab in Active Sjogren's Syndrome
NCT05350072Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2022
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of ianalumab in Sjogren's syndrome, sponsored by Novartis. Started Jul 2022; status: completed.
02
Drugs
ianalumab
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT05350072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05350072.